Center-Authored Papers

Filters: Author is Fromm, Jonathan R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2009
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
2012
Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, Greisman HA, Sabath DE, Wood BL, Robins H.  2012.  High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.. Science translational medicine. 4(134):134ra63. Abstract
Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK.  2012.  Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms.. Clinical lymphoma, myeloma & leukemia.
2014
Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D.  2014.  Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Abstract
Animals
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Antibody Development Core Facility
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Antigens, CD45
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Biologics Production Core Facility
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Cell Line, Tumor
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Cell Processing Core Facility
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Center-Authored Paper
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Clinical Research Division
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK.  2012.  Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms.. Clinical lymphoma, myeloma & leukemia.
Comparative Medicine Core Facility
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
DISEASE PROGRESSION
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Flow Cytometry Core Facility
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Genomics Core Facility
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Human Biology Division
Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D.  2014.  Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Abstract
Humans
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
Iodine Radioisotopes
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
June 2012
Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, Greisman HA, Sabath DE, Wood BL, Robins H.  2012.  High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.. Science translational medicine. 4(134):134ra63. Abstract
Lymphoma, T-Cell
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract
May 2012
Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK.  2012.  Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms.. Clinical lymphoma, myeloma & leukemia.
May 2014
Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D.  2014.  Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Abstract
MICE
Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW.  2009.  131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.. Blood. 113(23):5905-10. Abstract